Biotech firm Nektar Therapeutics outlines cash position targets while advancing its REZPEG BLA submission to 2029. Nektar Therapeutics expects to hold $800M to $825M in cash by the end of 2026, according to its Q1 2026 earnings call. The projection supports its pipeline, i
Biotech firm Nektar Therapeutics outlines cash position targets while advancing its REZPEG BLA submission to 2029.
Nektar Therapeutics expects to hold $800M to $825M in cash by the end of 2026, according to its Q1 2026 earnings call. The projection supports its pipeline, including the planned 2029 biologics license application for REZPEG.
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
